These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo. Reich R; Hoffman A; Suresh RR; Shai O; Frant J; Maresca A; Supuran CT; Breuer E J Enzyme Inhib Med Chem; 2015; 30(5):767-72. PubMed ID: 25669348 [TBL] [Abstract][Full Text] [Related]
23. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies. Li L; Zhu Z; Joshi B; Zhang C; Johnson CR; Marnett LJ; Honn KV; Crissman JD; Porter AT; Tang DG Anticancer Res; 1999; 19(1A):61-9. PubMed ID: 10226525 [TBL] [Abstract][Full Text] [Related]
24. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors. Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146 [TBL] [Abstract][Full Text] [Related]
25. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Wakabayashi C; Hasegawa H; Murata J; Saiki I Oncol Res; 1997; 9(8):411-7. PubMed ID: 9436194 [TBL] [Abstract][Full Text] [Related]
26. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. Hoffman A; Qadri B; Frant J; Katz Y; Bhusare SR; Breuer E; Hadar R; Reich R J Med Chem; 2008 Mar; 51(5):1406-14. PubMed ID: 18257543 [TBL] [Abstract][Full Text] [Related]